Rat CGRP-(8-37) TFA salt
产品说明书
 |
同义名 : | - |
| CAS号 : | N/A | |
| 货号 : | A1159618 | |
| 分子式 : | C140H225F3N42O43 | |
| 纯度 : | 98% | |
| 分子量 : | 3241.54 | |
| MDL号 : | N/A | |
| 存储条件： |
Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Rat CGRP-(8-37) TFA salt, a cholestanol-conjugated antagonist, accumulated in CLR(calcitonin receptor-like receptor)-containing endosomes and selectively inhibited CLR signaling in endosomes. CGRP8-37-cholestanol, but not unconjugated CGRP8-37, prevented sustained neuronal excitation. When injected intrathecally to mice, CGRP8-37-cholestanol inhibited nociceptive responses to intraplantar injection of capsaicin, formalin, or complete Freund's adjuvant more effectively than unconjugated CGRP8-37[3]. CGRP(8-37) is a truncated version of calcitonin gene-related peptide (CGRP) that binds to the CGRP receptor with similar affinity but does not activate the receptor and is a highly selective CGRP receptor antagonist. CGRP-(8-37) is effective in alleviating mechanical and thermal allodynia in a dose-dependent manner. The 50 nM dose is most efficacious for both forelimb and hindlimb responses. The period of efficacy is 10 min to onset for a duration of 20 min[4]. Intrathecal administration of 5 nmol or 10 nmol of CGRP-(8-37), but not 1 nmol, induces a significant increase in hindpaw withdrawal latency. Intrathecal administration of CGRP-(8-37) not only reverses the SP-induced decrease in latency to both withdrawal responses but also mediates a significant increase in response latency compared to basal levels[5]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
0.31mL 0.06mL 0.03mL |
1.54mL 0.31mL 0.15mL |
3.08mL 0.62mL 0.31mL |
| 参考文献 |
|---|